Press Releases April 30, 2026 04:01 PM

Arhaus to Announce First Quarter 2026 Financial Results on May 7, 2026

Arhaus, Inc. to Release Q1 2026 Financial Results and Host Earnings Call on May 7, 2026

By Maya Rios
Share
Twitter Reddit Facebook LinkedIn
ARHS

Arhaus, Inc., a premium home furnishings company, announced that it will release its first quarter 2026 financial results on May 7, 2026, before the market opens. The company will host a conference call and webcast to discuss the financial and operational results, emphasizing its vertically integrated model and commitment to responsibly sourced, artisan-crafted furniture.

Arhaus to Announce First Quarter 2026 Financial Results on May 7, 2026
ARHS
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Arhaus operates over 100 showroom locations across the U.S. and has a vertically integrated supply chain including a domestic manufacturing facility.
  • The company emphasizes a personalized client experience through an omni-channel approach including showrooms, interior design services, eCommerce, and catalog sales.
  • The Q1 2026 earnings announcement is scheduled prior to market open on May 7, 2026, with a subsequent investor call and webcast.

BOSTON HEIGHTS, Ohio, April 30, 2026 (GLOBE NEWSWIRE) -- Arhaus, Inc. (“Arhaus” or the “Company”) (NASDAQ: ARHS), a premium home furnishing brand known for responsibly sourced, artisan-crafted products and heirloom-quality design, will release its first quarter 2026 results on Thursday, May 7, 2026, before the stock market opens, followed by a conference call to review the Company’s financial and operational results at 8:30 a.m. Eastern Time.

A live webcast will be available at ir.arhaus.com.

To participate in the live call, dial:
U.S. Toll-Free: (877) 407-3982
International: 1 (201) 493-6780
Conference ID: 13758506

A telephone replay will be available for one week at:
U.S. Toll-Free: 1-844-512-2921
International: 1-412-317-6671
Conference ID: 13758506

A webcast replay will remain available at ir.arhaus.com for approximately 12 months.

About Arhaus
Founded in 1986 by Chief Executive Officer John Reed and his father, Arhaus is a premium home furnishings brand built on a simple idea: furniture and décor should be responsibly sourced, lovingly made, and built to last. Arhaus operates a vertically integrated model, designing and sourcing products directly from skilled artisans and carefully selected manufacturing partners around the world, including domestic upholstery production at its own North Carolina manufacturing facility. This approach enables Arhaus to offer a highly exclusive and customizable assortment of heirloom-quality furniture and décor designed to be used and enjoyed for generations.

With more than 100 Showroom locations across the United States, Arhaus’ integrated omni-channel model connects every client touchpoint, from Showroom and interior design to eCommerce and catalog, allowing Arhaus to meet clients wherever and however they choose to shop while delivering a highly personalized client-first experience from discovery through delivery.

For more information, please visit www.arhaus.com.

Investor Contact:
Tara Louise Atwood-Saja
Vice President, Investor Relations
(440) 439-7700
invest@arhaus.com


Risks

  • Financial results may not meet investor expectations, potentially impacting stock performance.
  • Supply chain disruptions or increased costs could affect production and margins, relevant to the manufacturing and retail sectors.
  • Market demand fluctuations for premium home furnishings could influence future financial performance and growth prospects.

More from Press Releases

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 Jun 14, 2026 Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026) Jun 14, 2026 Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Jun 14, 2026